Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MGAM | O43451 | 1/20 | 0.56 |
| ▸ | SI | P14410 | 1/20 | 0.56 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19216681 | 0.92 | GAA (0.52) | GAAMGAMSIMGAM2ALOX15 | |
| SCHEMBL1617803 | 0.87 | GAA (0.47) | GAAMGAMSIMGAM2ALOX15 | |
| SCHEMBL17092379 | 0.83 | ALOX15 (0.43) | GAAMGAMSIMGAM2ALOX15 | |
| SCHEMBL19216698 | 0.82 | GAA (0.50) | GAAMGAMSIMGAM2ALOX15 | |
| SCHEMBL19216683 | 0.81 | GAA (0.48) | GAAMGAMSIMGAM2ALOX15 | |
| SCHEMBL3531364 | 0.80 | MGAM (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL26976622 | 0.80 | ALDH1A1 (0.37) | GAAMGAMSIMGAM2ALOX15 | |
| SCHEMBL17520063 | 0.78 | GAA (0.54) | GAAMGAMSIMGAM2ALOX15 | |
| SCHEMBL9598083 | 0.78 | GAA (0.54) | GAAMGAMSIMGAM2ALOX15 | |
| SCHEMBL24309459 | 0.77 | GAA (0.58) | GAAMGAMSIMGAM2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197703-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-3880676-B1 | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PFIZER (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-4143186-A1 | AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | Pfizer Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115698004-A | Azalactam compounds as HPK1 inhibitors | 辉瑞公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-11267824-B2 | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-03-08 | — | — | US | disclosed |
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | disclosed |
| WO-2021220185-A1 | AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | PFIZER INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-11142525-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2021-10-12 | — | — | US | disclosed |
| CN-110997682-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2020-04-10 | — | — | CN | disclosed |
| EP-3202766-B1 | ISOXAZOLE DERIVATIVE AS MUTATED ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO CO LTD (JP) | 2019-12-25 | — | — | EP | disclosed |
| WO-2019034725-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-02-21 | — | — | WO | disclosed |
| US-10040791-B2 | Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-08-07 | — | — | US | disclosed |
| US-10040791-B2 | Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-08-07 | — | — | US | disclosed |
| US-20170313696-A1 | ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| US-20170313696-A1 | ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| EP-3202766-A1 | ISOXAZOLE DERIVATIVE AS MUTATED ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-09 | — | — | EP | disclosed |
| EP-3202766-A1 | ISOXAZOLE DERIVATIVE AS MUTATED ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-09 | — | — | EP | disclosed |
| WO-2009068512-A1 | 2 -AMINO-PYRIMIDINE DERIVATIVES AS HISTAMINE H4 ANTAGONISTS | PALAU PHARMA, S. A. (ES) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313696-A1 | ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR | IDH1, IDH3A, IDH3B | GAA 462/4885MGAM 789/4885SI 3293/4885 |
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | GAA 3824/4885MGAM 1637/4885SI 3217/4885 |
| US-10040791-B2 | Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor | IDH1, IDH3A, IDH3B | GAA 462/4885MGAM 789/4885SI 3293/4885 |
| US-11142525-B2 | Azalactam compounds as HPK1 inhibitors | CDKN1A, HIPK1, CMPK1 | GAA 3261/4885MGAM 1583/4885SI 3181/4885 |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | CDKN1A, HIPK1, CMPK1 | GAA 3824/4885MGAM 1637/4885SI 3217/4885 |
| US-20240197703-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | GAA 3824/4885MGAM 1637/4885SI 3217/4885 |
| US-11267824-B2 | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase | IDO2, IDO1, TDO2 | GAA 543/4885MGAM 379/4885SI 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.